Kyorin Pharmaceutical, a subsidiary of Kyorin Holdings, Inc. and Sumitomo Pharma, in Japan, have entered into a license agreement for development, manufacturing, and commercialisation of a therapeutic agent for overactive bladder (OAB) called Vibegron as international nonproprietary name (INN), in Taiwan, Hong Kong, Singapore, Indonesia, and Vietnam.
Kyorin and Sumitomo to introduce drug for overactive bladder in Taiwan & other Asian countries
Kyorin Pharmaceutical Co, Ltd, a subsidiary of Kyorin Holdings Inc, and Eisai Co., Ltd have entered into a license agreement for development and distribution of Vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei.